AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy

Overview of attention for article published in Journal of Hematology & Oncology, August 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news: 1 news outlet
twitter: 8 X users

patent: 1 patent

Citations

dimensions_citation: 84 Dimensions

Readers on

mendeley: 110 Mendeley

Summary News X Patents Dimensions citations

So far, Altmetric has seen 1 news story.

Affimed Shifts Attention To Risky Combination Therapy With NK Cells For T-Cell Lymphoma

Seeking Alpha, 17 Feb 2023

Follow Summary Affimed has decided to focus on testing AFM13 in combination with Artiva's AB-101 NK cell product for the…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.